Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 4/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | AKT2 | P31751 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.30 |
| ▸ | CDK9 | P50750 | 1/20 | 0.30 |
| ▸ | FURIN | P09958 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5407968 | 1.00 | ULK1 (0.36) | ULK1ROCK1PIM1CHEK1KCNH2 | |
| SCHEMBL5413115 | 1.00 | ULK1 (0.36) | ULK1ROCK1PIM1CHEK1KCNH2 | |
| SCHEMBL5413111 | 1.00 | ULK1 (0.36) | ULK1ROCK1PIM1CHEK1KCNH2 | |
| SCHEMBL5407972 | 1.00 | ULK1 (0.36) | ULK1ROCK1PIM1CHEK1KCNH2 | |
| SCHEMBL5419190 | 0.89 | ULK1 (0.35) | ULK1ROCK1PIM1CHEK1KCNH2 | |
| SCHEMBL5416107 | 0.89 | ULK1 (0.35) | ULK1ROCK1PIM1CHEK1KCNH2 | |
| SCHEMBL5416102 | 0.89 | ULK1 (0.35) | ULK1ROCK1PIM1CHEK1KCNH2 | |
| SCHEMBL5416098 | 0.89 | ULK1 (0.35) | ULK1ROCK1PIM1CHEK1KCNH2 | |
| SCHEMBL5419184 | 0.89 | ULK1 (0.35) | ULK1ROCK1PIM1CHEK1KCNH2 | |
| SCHEMBL5409278 | 0.85 | AKT2 (0.33) | AKT2CDK2FLT3CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | ULK1 1090/4885ROCK1 1/4885PIM1 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.